When we introduced the Nasdaq IPO Pulse a year ago, we said it suggested that U.S. “IPO activity… should remain in an uptrend” as we headed into 2024. Then, when we introduced the Nasdaq ...

For over 50 years, Nasdaq has been a leader in the exchange space through our technology innovations. We built our IPO process in partnership with the investment banking community, ensuring that ...

The oil and natural gas producer, backed by private equity firms Pearl Energy Investments and NGP, priced its IPO at $20 per share, within the expected range of $18 to $21. The stock opened at $22 ...

The Indian primary market remains robust amid secondary market volatility, with 29 companies listing in January, driven by ...

The IPO market may see a resurgence in 2025, with Wall Street banks gearing up for increased activity as private equity firms look to the equities market to divest high-profile assets. Companies ...

See the 10 stocks » ConocoPhillips has undergone a lot ... In other words, investors who bought one share at the company's IPO would have owned two shares following that split.

Those units not separated will continue to trade on the Nasdaq under the symbol “NOEMU ... and prospectus for its initial public offering (IPO) filed with the SEC. Copies are available ...

This trend is further evidenced by the 66 IPOs listed on Nasdaq during the first half of 2024, representing a 71% success rate for Nasdaq-eligible operating company IPOs in the U.S. market.

In case you haven't heard, there's a new president in town, and he's determined to shake up the Washington, D.C.

Here's the key takeaway: Every share of McDonald's bought at the company's IPO would have become 729 ... what they believe are the 10 best stocks for investors to buy now… and McDonald's wasn ...

Nasdaq president Nelson Griggs discusses the decline of companies going public and when the incentive for initial public ...

Maze Therapeutics ( NASDAQ: MAZE) shares were trading largely flat following a $140M initial public offering. Shares of the kidney disease drug developer opened at $16 per share after being priced at ...